Feedback
Settings

Settings

Goto Application

1. WO2021188620 - PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

PermaLink
Publication Number WO/2021/188620
Publication Date 23.09.2021
International Application No. PCT/US2021/022680
International Filing Date 17.03.2021
IPC
C07D 263/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
263Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
02not condensed with other rings
08having one double bond between ring members or between a ring member and a non-ring member
10with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 211/76 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
68having one double bond between ring members or between a ring member and a non-ring member
72with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
74Oxygen atoms
76attached in position 2 or 6
C07D 213/40 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
24with substituted hydrocarbon radicals attached to ring carbon atoms
36Radicals substituted by singly-bound nitrogen atoms
40Acylated substituent nitrogen atom
C07D 223/16 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
223Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
14condensed with carbocyclic rings or ring systems
16Benzazepines; Hydrogenated benzazepines
C07D 267/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
267Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
02Seven-membered rings
08having the hetero atoms in positions 1 and 4
12condensed with carbocyclic rings or ring systems
14condensed with one six-membered ring
C07D 273/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/-C07D271/183
CPC
A61K 31/222
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
222with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/553
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
553having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/662
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Applicants
  • COCRYSTAL PHARMA INC. [US]/[US]
Inventors
  • JACOBSON, Irina C.
  • LEE, Sam SK
  • PIZARRO NOVOA, Juan Carlos
Agents
  • VOELKER, Alden E.
  • DANEK, Shelley C.
Priority Data
62/990,72117.03.2020US
63/027,49220.05.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION
(FR) DÉRIVÉS DE N5-MÉTHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE PEPTIDOMIMÉTIQUES, DÉRIVÉS DE TRIAZASPIRO[4.14]NONADÉCANE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
front page image
Abstract
(EN) Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).
(FR) L'invention concerne des dérivés de N5-méthyl-N2-(nonanoyl-L-leucyl)-L-glutaminate, des dérivés de triazaspiro[4.14]nonadécane et des composés similaires destinés à être utilisés dans des procédés d'inhibition de la réplication de norovirus et de coronavirus dans un échantillon biologique ou chez un patient, de réduction de la quantité de norovirus ou de coronavirus dans un échantillon biologique ou chez un patient, et destinés au traitement de norovirus et de coronavirus chez un patient, comprenant l'administration audit échantillon biologique ou patient d'une quantité sûre et efficace d'un composé représenté par les formules I ou II, ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne la synthèse et la caractérisation de composés donnés à titre d'exemple ainsi que des données pharmacologiques associées (par ex., page 99 à pag 271; exemple 1 à 3; composés A1 à A104 et B1 à B66; tables A à E).
Latest bibliographic data on file with the International Bureau
# -